Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition combined with chemoradiotherapy±ICIs for local advanced patients with inoperable esophageal squamous cell carcinoma. The main questions it aims to answer are: • If the feasibility and safety of whole-course immunonutrition combined with chemoradiotherapy±ICIs is better. • If the survival benefits (1, 2 and 3-years progression free survival) of whole-course immunonutrition combined with chemoradiotherapy±ICIs is longer. The Experimental group will receive a combination immunonutrition of omega-3 fatty acids, and glutamine, whereas the control group will receive standard formula.
Study Type
OBSERVATIONAL
Enrollment
70
The Experimental group received a combination of omega-3 fatty acids, and glutamine, whereas the control group received standard formula.
Anhui provincial hospital
Hefei, China
RECRUITINGRate of adverse events
Rate of adverse events (CTCAE V4.0)
Time frame: 1 month post treatment
Disease Control Rate
Disease Control Rate
Time frame: 1 month post treatment
1-, 2-, 3-year Progression-free survival rate (PFS).
1-, 2-, 3-year Progression-free survival rate (PFS).
Time frame: 1 to 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.